JP2002532549A - ５ｈｔ３−受容体−アンタゴニストの使用 - Google Patents
５ｈｔ３−受容体−アンタゴニストの使用Info
- Publication number
- JP2002532549A JP2002532549A JP2000589184A JP2000589184A JP2002532549A JP 2002532549 A JP2002532549 A JP 2002532549A JP 2000589184 A JP2000589184 A JP 2000589184A JP 2000589184 A JP2000589184 A JP 2000589184A JP 2002532549 A JP2002532549 A JP 2002532549A
- Authority
- JP
- Japan
- Prior art keywords
- fatigue
- cfs
- patients
- receptor
- active substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229940044551 receptor antagonist Drugs 0.000 title description 2
- 239000002464 receptor antagonist Substances 0.000 title description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims abstract description 27
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 5
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 239000005557 antagonist Substances 0.000 claims abstract description 3
- 239000013543 active substance Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 8
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims description 5
- 229960005343 ondansetron Drugs 0.000 claims description 5
- 229960003688 tropisetron Drugs 0.000 claims description 5
- UIVFDCIXTSJXBB-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C[C]2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CN=C21 UIVFDCIXTSJXBB-ITGUQSILSA-N 0.000 claims description 5
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 claims description 4
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 claims description 3
- 229960003727 granisetron Drugs 0.000 claims description 3
- FLZQKRKHLSUHOR-UHFFFAOYSA-N alosetron Chemical compound CC1=NC=N[C]1CN1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FLZQKRKHLSUHOR-UHFFFAOYSA-N 0.000 claims description 2
- 229960003550 alosetron Drugs 0.000 claims description 2
- MNJNPLVXBISNSX-WDNDVIMCSA-N bemesetron Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C1=CC(Cl)=CC(Cl)=C1 MNJNPLVXBISNSX-WDNDVIMCSA-N 0.000 claims description 2
- 229950007840 bemesetron Drugs 0.000 claims description 2
- 239000006207 intravenous dosage form Substances 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 12
- 206010016256 fatigue Diseases 0.000 description 25
- 208000024891 symptom Diseases 0.000 description 14
- 230000000694 effects Effects 0.000 description 10
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 10
- 239000000126 substance Substances 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 229940076279 serotonin Drugs 0.000 description 5
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229960002464 fluoxetine Drugs 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000000935 antidepressant agent Substances 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000003862 health status Effects 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000034048 Asymptomatic disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 230000007103 stamina Effects 0.000 description 1
- 238000004330 variable angle spinning Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19859406 | 1998-12-22 | ||
| DE19859406.2 | 1998-12-22 | ||
| PCT/DE1999/004071 WO2000037073A1 (de) | 1998-12-22 | 1999-12-22 | Verwendung von 5ht3-rezeptor-antagonisten zur therapie des chronischen müdigkeitssyndrom |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2002532549A true JP2002532549A (ja) | 2002-10-02 |
Family
ID=7892223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000589184A Withdrawn JP2002532549A (ja) | 1998-12-22 | 1999-12-22 | ５ｈｔ３−受容体−アンタゴニストの使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US6740672B1 (de) |
| EP (1) | EP1140076A1 (de) |
| JP (1) | JP2002532549A (de) |
| CN (1) | CN1161118C (de) |
| AU (1) | AU759250B2 (de) |
| BR (1) | BR9916495A (de) |
| CA (1) | CA2356246A1 (de) |
| MX (1) | MXPA01006319A (de) |
| WO (1) | WO2000037073A1 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004014429A1 (ja) * | 2002-08-09 | 2004-02-19 | Mitsubishi Pharma Corporation | 精神疾患発症脆弱性制御剤 |
| KR20070114748A (ko) | 2005-02-17 | 2007-12-04 | 에이엠알 테크놀로지, 인크. | Ｃｉｎｖ 및 ｉｂｓｄ를 치료하기 위한 벤족사졸카복스아미드 |
| WO2011008572A2 (en) | 2009-07-14 | 2011-01-20 | Albany Molecular Research, Inc. | 5-ht3 receptor modulators, methods of making, and use thereof |
| KR101778439B1 (ko) | 2015-04-27 | 2017-09-14 | 울산대학교 산학협력단 | 자연살해세포 활성화제를 유효성분으로 함유하는 면역증강 및 항암활성증진용 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4695578A (en) * | 1984-01-25 | 1987-09-22 | Glaxo Group Limited | 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances |
| JPH06508836A (ja) * | 1991-06-26 | 1994-10-06 | セプラコア，インコーポレーテッド | 光学的に純粋なｒ（＋）オンダンセトロンを使用する嘔吐、吐き気および他の障害の治療のための方法および組成物 |
| GB9412995D0 (en) * | 1994-06-28 | 1994-10-26 | Prendergast Kenneth F | Safety enhancing pharmaceutical compositions of an active indazole |
| ZA958725B (en) * | 1994-10-20 | 1997-04-16 | Lilly Co Eli | Treatment of disorders with duloxetine |
| US5614523A (en) * | 1995-01-17 | 1997-03-25 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
-
1999
- 1999-12-22 CA CA002356246A patent/CA2356246A1/en not_active Abandoned
- 1999-12-22 US US09/868,972 patent/US6740672B1/en not_active Expired - Fee Related
- 1999-12-22 EP EP99967889A patent/EP1140076A1/de not_active Withdrawn
- 1999-12-22 BR BR9916495-7A patent/BR9916495A/pt not_active IP Right Cessation
- 1999-12-22 JP JP2000589184A patent/JP2002532549A/ja not_active Withdrawn
- 1999-12-22 AU AU24285/00A patent/AU759250B2/en not_active Ceased
- 1999-12-22 WO PCT/DE1999/004071 patent/WO2000037073A1/de not_active Application Discontinuation
- 1999-12-22 CN CNB998158445A patent/CN1161118C/zh not_active Expired - Fee Related
- 1999-12-22 MX MXPA01006319A patent/MXPA01006319A/es unknown
-
2004
- 2004-04-30 US US10/837,370 patent/US20040204467A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN1161118C (zh) | 2004-08-11 |
| AU759250B2 (en) | 2003-04-10 |
| CN1333684A (zh) | 2002-01-30 |
| WO2000037073A1 (de) | 2000-06-29 |
| US20040204467A1 (en) | 2004-10-14 |
| BR9916495A (pt) | 2001-09-04 |
| EP1140076A1 (de) | 2001-10-10 |
| CA2356246A1 (en) | 2000-06-29 |
| MXPA01006319A (es) | 2003-06-06 |
| AU2428500A (en) | 2000-07-12 |
| US6740672B1 (en) | 2004-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nitti et al. | Safety and tolerability of the β3‐adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12‐week randomised Phase III trials and of a 1‐year randomised Phase III trial | |
| Grushka et al. | Burning mouth syndrome | |
| US20210236523A1 (en) | Psychedelic treatment for headache disorders | |
| Salloum et al. | Naltrexone utility in depressed alcoholics | |
| Gurley et al. | Medicinal marijuana: a comprehensive review | |
| HU229150B1 (hu) | Gyorsan ható szelektív szerotonin-újrafelvételt gátlókat alkalmazó eljárások nemi mûködési zavarok kezelésére | |
| Kim et al. | Effect of 0.1% pilocarpine mouthwash on xerostomia: double‐blind, randomised controlled trial | |
| Moore et al. | Hemostatic and anesthetic efficacy of 4% articaine HCl with 1: 200,000 epinephrine and 4% articaine HCl with 1: 100,000 epinephrine when administered intraorally for periodontal surgery | |
| Berlin et al. | Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation | |
| CN109862895A (zh) | 结节性痒疹的治疗 | |
| Ghose et al. | Intravenous tyramine response in migraine before and during treatment with indoramin. | |
| Azemati et al. | Analgesic Characteristics of Bupivacaine Alone and in Combination with Dexmedetomidine or Meperidine in Spinal Anesthesia during Cesarean Section: A Double‐Blind Randomized Clinical Trial Study | |
| JP2002532549A (ja) | ５ｈｔ３−受容体−アンタゴニストの使用 | |
| JP2001515479A (ja) | 偏頭痛治療におけるレボブピバカインまたはロピバカインの使用 | |
| JP6514420B2 (ja) | 睡眠時無呼吸の処置のためのスルチアム | |
| US20230000796A1 (en) | Intranasal administration of ketamine to cluster headache patients | |
| Albazzaz et al. | Effect of azelastine on bronchoconstriction induced by histamine and leukotriene C4 in patients with extrinsic asthma. | |
| Huey et al. | Clinical evaluation of intravenous labetalol for the treatment of hypertensive urgency | |
| JPH11500739A (ja) | 脳浮腫処置用アセタゾールアミドの治療用途 | |
| TW202131910A (zh) | 使用mtorc1調節劑的治療方法 | |
| CN103501609A (zh) | 用于偏头痛的治疗 | |
| JP2003535897A (ja) | アンギオテンシンｉｉアンタゴニストの新規使用法 | |
| KR20170005415A (ko) | 과수면증의 치료 방법 | |
| TW200528098A (en) | Treatment of insomnia in human patients | |
| CA3077162C (en) | Treatment for therapy refractory depression comprising glycyrrhizic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A300 | Application deemed to be withdrawn because no request for examination was validly filed |
Free format text: JAPANESE INTERMEDIATE CODE: A300 Effective date: 20070306 |